Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Kyowa Hakko Kirin posted modest gains in its pharmaceutical business at its announcement of interim results as expectation rides on the eventual outcome of KW-0761, a humanized anti-CCR-4 monoclonal antibody being developed by Kyowa for hematological cancer applications in Japan and the U.S. and by licensing partner Amgen in the U.K. for allergy application
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC075500

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel